M. Di Maio, G. Daniele, and M. Piccirillo, “Impact on health-related quality of life of the addition of bevacizumab to first-line chemotherapy for ovarian cancer:  ”, CBN, vol. 1, no. 1, pp. 33–35, Oct. 2013.